<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00421213</url>
  </required_header>
  <id_info>
    <org_study_id>SGL2003</org_study_id>
    <nct_id>NCT00421213</nct_id>
  </id_info>
  <brief_title>Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers</brief_title>
  <official_title>Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziopharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziopharm</source>
  <brief_summary>
    <textblock>
      The study of safety of a new organic arsenic compound in the treatment of hematological
      malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>toxicities</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hematologic Neoplasms</condition>
  <condition>Bone Marrow Neoplasms</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darinaparsin</intervention_name>
    <description>300mg/m2 of Darinaparsin given daily for five consecutive days to be repeated every 28 days for up to six months.</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>ZIO-101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Hodgkin's or non-Hodgkin's Lymphoma.

          2. ≥ 1 prior therapy and currently requiring therapy.

          3. Evaluable disease (defined by disease-specific criteria listed in Appendix 1)

          4. ≥ 18 years of age.

          5. ECOG performance score ≤ 2 (see Appendix 2).

          6. Life-expectancy ≥ 2 months.

          7. Written informed consent in compliance with ZIOPHARM policies and the Human
             Investigation Review Committee with jurisdiction over the site.

          8. No anti-cancer therapy exception of hydroxyurea ≤ 3 weeks before Baseline (Day 1,
             Cycle 1).

          9. The following clinical laboratory values &lt; 2 weeks before Baseline:

               -  Creatinine ≤ 2X upper limit of normal (ULN).

               -  Total bilirubin ≤ 2X ULN.

               -  Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 3X ULN.

        Exclusion Criteria

          1. New York Heart Association (NYHA) functional class ≥3 myocardial infarction (see
             Appendix ) within 6 months before Baseline or uncontrolled cardiac arrhythmia other
             than asymptomatic atrial fibrillation; a QTc ≥450 msec; or a ≥grade-2 atrioventricular
             (AV) block or left bundle branch block (LBBB).

          2. Pregnant and/or lactating female. (Women of childbearing age must use effective
             contraception from Screening through the duration of study participation).

          3. Uncontrolled infection.

          4. Prior seizures ≥ grade-3 in CTC v.3 criteria.

          5. Arsenic allergy.

          6. Significant neuropathology, defined as grade &gt; 2 per CTCAE Version 3.0.

          7. Confusion or dementia.

          8. Prior history of neurological deficits (e.g., stroke, dementia, ischemia) that has the
             potential to confound a post-dose neurological assessment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <last_update_submitted>July 18, 2012</last_update_submitted>
  <last_update_submitted_qc>July 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>APL</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>T-cell Lymphoma</keyword>
  <keyword>Peripheral T-cell Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

